| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Khurram Jamil is Chief Medical Officer at GALT. Khurram Jamil's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider.
Our model assigns Khurram Jamil a below-average insider score of 36/100, based on 12 past trades. Over a 12-month horizon, the one trade was not profitable, with an average 12-month return of -100.0%.
Khurram Jamil has 12 Form 4 filings on record from August 2024 to July 2026, all as Chief Medical Officer at Galectin Therapeutics (GALT), 2024–2026.
The 38 reported transactions were 18 open-market sales, 14 option exercises and 6 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 9 sales worth about $1.4M.
The largest open-market sale was 121,117 shares of GALT at an average $5.47 on November 13, 2025, about $663K.
All 9 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | GALT Galectin Therapeutics Inc. | Chief Medical Officer | Sale+OE10b5-1 | 16,250 | $5.13 | $83,284.50 | - | -27.5% | - | |
| Jun 29, 2026 | GALT Galectin Therapeutics Inc. | Chief Medical Officer | Sale+OE10b5-1 | 52,037 | $5.04 | $262,083.68 | - | -20.9% | - | |
| Jun 23, 2026 | GALT Galectin Therapeutics Inc. | Chief Medical Officer | Sale+OE10b5-1 | 7,557 | $3.14 | $23,728.98 | - | +26.9% | - | |
| May 26, 2026 | GALT Galectin Therapeutics Inc. | Chief Medical Officer | Sale+OE10b5-1 | 568 | $3.10 | $1,761.03 | - | +39.1% | - | |
| Jan 6, 2026 | GALT Galectin Therapeutics Inc | Chief Medical Officer | Sale+OE10b5-1 | 60,000 | $3.87 | $232,402.06 | - | -25.8% | - | |
| Dec 31, 2025 | GALT Galectin Therapeutics Inc | Chief Medical Officer | Sale+OE10b5-1 | 8,125 | $4.07 | $33,089.06 | - | -32.9% | - | |
| Dec 17, 2025 | GALT Galectin Therapeutics Inc | Chief Medical Officer | Sale+OE10b5-1 | 19,442 | $7.04 | $136,871.68 | - | -51.3% | - | |
| Nov 13, 2025 | GALT Galectin Therapeutics Inc | Chief Medical Officer | Sale+OE10b5-1 | 121,117 | $5.47 | $662,509.99 | -96.4% | -50.1% | - | |
| Dec 23, 2024 | GALT Galectin Therapeutics Inc | Chief Medical Officer | Sale+OE10b5-1 | 13,654 | $0.88 | $12,044.19 | -34.1% | +85.4% | +348.3% |